On December 12, 2025, Fortress Biotech, Inc. amended its credit agreement, extending the loan maturity to June 30, 2028, with a current loan balance of approximately $29.5 million and requiring Journey Medical Corporation to achieve escalating net sales targets of $60 million to $80 million by December 31, 2026.